Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials / M. Gheorghiade, M.A. Konstam, J.C. Burnett, L. Grinfeld, A.P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi, P. Agostoni. - In: JAMA. - ISSN 0098-7484. - 297:12(2007 Mar 28), pp. 1332-1343.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

P. Agostoni
2007

Abstract

Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.
Administration, Oral ; Heart Failure ; Double-Blind Method ; Benzazepines ; Humans ; Receptors, Vasopressin ; Diuretics ; Aged ; Cardiovascular Agents ; Furosemide ; Drug Therapy, Combination ; Hospitalization ; Aged, 80 and over ; Adult ; Middle Aged ; Male ; Female
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
28-mar-2007
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/190711
Citazioni
  • ???jsp.display-item.citation.pmc??? 167
  • Scopus 750
  • ???jsp.display-item.citation.isi??? 630
social impact